Insulet Corporation (PODD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Insulet Corporation (PODD) has a cash flow conversion efficiency ratio of 0.087x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($113.80 Million) by net assets ($1.30 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PODD cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Insulet Corporation - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Insulet Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Insulet Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Insulet Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Orient Sec Co Ltd
SHG:600958
|
0.133x |
|
Samsara Inc
NYSE:IOT
|
0.049x |
|
Fujikura Ltd
NYSE:FJIKY
|
N/A |
|
Antero Resources Corp
NYSE:AR
|
0.104x |
|
BrightSpring Health Services, Inc. Common Stock
NASDAQ:BTSG
|
0.062x |
|
Erie Indemnity Company
NASDAQ:ERIE
|
0.039x |
|
SK Innovation
KO:096770
|
0.056x |
|
Hero MotoCorp Limited
NSE:HEROMOTOCO
|
0.164x |
Annual Cash Flow Conversion Efficiency for Insulet Corporation (2004–2025)
The table below shows the annual cash flow conversion efficiency of Insulet Corporation from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see PODD market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.52 Billion | $569.30 Million | 0.376x | +5.79% |
| 2024-12-31 | $1.21 Billion | $430.30 Million | 0.355x | +78.60% |
| 2023-12-31 | $732.70 Million | $145.70 Million | 0.199x | -20.39% |
| 2022-12-31 | $476.40 Million | $119.00 Million | 0.250x | +304.05% |
| 2021-12-31 | $556.30 Million | $-68.10 Million | -0.122x | -187.96% |
| 2020-12-31 | $603.60 Million | $84.00 Million | 0.139x | -89.27% |
| 2019-12-31 | $75.90 Million | $98.40 Million | 1.296x | +665.94% |
| 2018-12-31 | $212.10 Million | $35.90 Million | 0.169x | -35.04% |
| 2017-12-31 | $158.52 Million | $41.30 Million | 0.261x | +3.41% |
| 2016-12-31 | $63.15 Million | $15.91 Million | 0.252x | +168.35% |
| 2015-12-31 | $34.05 Million | $-12.55 Million | -0.369x | -446.43% |
| 2014-12-31 | $83.83 Million | $8.92 Million | 0.106x | +296.00% |
| 2013-12-31 | $124.60 Million | $3.35 Million | 0.027x | +104.08% |
| 2012-12-31 | $44.18 Million | $-29.06 Million | -0.658x | -84.52% |
| 2011-12-31 | $71.40 Million | $-25.45 Million | -0.356x | +33.72% |
| 2010-12-31 | $66.23 Million | $-35.62 Million | -0.538x | +42.36% |
| 2009-12-31 | $52.86 Million | $-49.32 Million | -0.933x | +95.17% |
| 2008-12-31 | $4.27 Million | $-82.61 Million | -19.329x | -3440.77% |
| 2007-12-31 | $92.28 Million | $-50.37 Million | -0.546x | -274.58% |
| 2006-12-31 | $-101.77 Million | $-31.82 Million | 0.313x | +1.69% |
| 2005-12-31 | $-66.09 Million | $-20.32 Million | 0.307x | +4.82% |
| 2004-12-31 | $-44.51 Million | $-13.06 Million | 0.293x | -- |
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain… Read more